JCRB1095 KYSE150
Cell information
Important Notice(s)On the MTA of KYSE series cell lines with Kyoto University (for profit organizations)
Announcement of unavailability of KYSE series cell lines to oversea users outside of Japan
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1095 | Cell Name | KYSE150 |
|---|---|---|---|
| Profile | Poorly differentiated squamous carcinoma cell line from human esophageal cancer. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | 49 |
| Identity | available | Tissue for Primary Cancer | esophagus |
| Case history | esophageal cancer | Metastasis | |
| Tissue Metastasized | Genetics | modal chromosome number = 84XX | |
| Life Span | infinite | Crisis PDL | |
| Morphology | epithelial-like | Character | |
| Classify | tumor | Established by | Shimada,Y. et al. |
| Registered by | Shimada,Y. | Regulation for Distribution | Cite reference {5368}. Company users require MTA from the originator. See additional information. |
| Comment | Distribution restricted to Japan(domestic use only). | Year | 2003 |
| Medium | Ham's F12 medium with 2% fetal bovine serum. | Methods for Passages | |
| Cell Number on Passage | Race | Japanese | |
| CO2 Conc. | 5 % | Tissue Sampling | esophagus |
| Tissue Type | poorly differentiated squamous carcinoma |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:11520067 | Gene expression profiling in human esophageal cancers using cDNA microarray. Kan T,Shimada Y,Sato F,Maeda M,Kawabe A,Kaganoi J,Itami A,Yamasaki S,Imamura M Biochem Biophys Res Commun. 2001 Aug 31;286(4):792-801 |
| Pubmed id:10995879 | PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Ding Y,Shimada Y,Kano M,Itami A,Kawabe A,Maeda M,Li Z,Hong T,Sato F,Kaganoi J,Imamura M Int J Oncol. 2000 Oct;17(4):695-9 |
| Pubmed id:10362086 | Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. Kanaoka S,Yamasaki S,Okino T,Inoue N,Shimada Y,Kaneko M,Otaka A,Fujii N,Imamura M J Surg Oncol. 1999 May;71(1):16-21 |
| Pubmed id:8486532 | Hyperthermic enhancement of cytotoxicity and increased uptake of cis-diamminedichloroplatinum(II) in cultured human esophageal cancer cells. Miyahara T,Ueda K,Akaboshi M,Shimada Y,Imamura M,Utsumi H Jpn J Cancer Res. 1993 Mar;84(3):336-40 |
| Images |
|---|
   |
| Movies |
|---|
|
LOT Information
| Cell No. | JCRB1095 | Cell Name | KYSE150 |
|---|---|---|---|
| LOT No. | 12112008 | Lot Specification | distribution |
| Medium | Ham's F12 medium with 2% fetal bovine serum | Temperature | 37 C |
| Cell Density at Seeding | 6 - 8 x 10^4 cells/ml | Methods for Passages | 0.25% trypsin and 0.02% EDTA |
| Doubling Time | approx. 2 days | Cell Number in Vial (cells/1ml) | 1.1 x 10^6 |
| Viability at cell freezing (%) | 95 | Antibiotics Used | free (pretreated with MC-210 and BM cycline) |
| Passage Number | Unknown (10 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B), MD. |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | D5S818:12,13 D13S317:8,11 D7S820:10,11 D16S539:9,11 VWA:16,17 TH01:7,9 AM:X TPOX:8 CSF1PO:12,13 |
|
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20%& FBS - Ham's F12 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | JCRB1095 | Cell Name | |
|---|---|---|---|
| LOT No. | 08272007 | Lot Specification | distribution |
| Medium | Ham's F12 medium with 2% fetal calf serum lotGIBCI484375 | Temperature | 37 |
| Cell Density at Seeding | 3-4 x10^4cells/ml | Methods for Passages | 0.25% trypsin and 0.02% EDTA in PBS |
| Doubling Time | 85hr | Cell Number in Vial (cells/1ml) | 2.8 x 10^6 cells |
| Viability at cell freezing (%) | 96 | Antibiotics Used | free |
| Passage Number | P6* | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | Confirmed as human by NP, G6PD (type B) AST |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FCS-culture medium | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | JCRB1095 | Cell Name | KYSE150 |
|---|---|---|---|
| LOT No. | 12102015 | Lot Specification | distribution |
| Medium | Ham's F12 medium(SIGMA,N6658) with 5% heat inactivated fetal bovine serum(SIGMA12J396) | Temperature | 37 C |
| Cell Density at Seeding | 0.3-1.0x10^5 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25%trypsin(GIBCO) and 0.02% EDTA(1/3 split) once a week. |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.6x10^6 |
| Viability at cell freezing (%) | 96.3 | Antibiotics Used | free |
| Passage Number | p10* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:12,13 D13S317:8,11 D7S820:10,11 D16S539:9,11 VWA:16,17 TH01:7,9 AM:X TPOX:8 CSF1PO:12,13 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |